How to access Austedo for Huntington's chorea or tardive dyskinesia from the UAE: 2026 pathway via UAE movement disorders neurology and community pharmacy supply

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

The UAE has one of the deepest adult neurology and movement disorders service networks in the wider region. Cleveland Clinic Abu Dhabi runs a movement disorders programme with subspecialty fellowship-trained neurologists, video-based dyskinesia assessment, and integrated psychiatry input. American Hospital Dubai neurology, Mediclinic City Hospital neurology, Sheikh Shakhbout Medical City (SSMC) neurology, Burjeel Medical City neurology, NMC Specialty neurology, the Dr Sulaiman Al Habib network, and the German Neuroscience Centre Dubai all manage movement disorders cases including Huntington's chorea and tardive dyskinesia. For the psychiatric-comorbid tardive dyskinesia population, Maudsley Health (NMC) Abu Dhabi, Priory Wellbeing Centre Dubai, and American Hospital psychiatry are the routine prescribing partners alongside the neurology services. Austedo (deutetrabenazine; once-daily extended-release variant Austedo XR) is the selective VMAT2 inhibitor from Teva Pharmaceuticals, approved by the FDA in 2017 for chorea associated with Huntington's disease in adults and for tardive dyskinesia in adults. For a UAE-resident adult patient with confirmed Huntington's chorea or moderate-to-severe tardive dyskinesia, the operational question is no longer whether a VMAT2 inhibitor pathway is reachable: it is which prescribing centre fits the case, whether the local supply runs as in-country Austedo or as a named-patient import, what the insurance pre-authorisation conversation looks like, what the structured depression and suicidality monitoring schedule looks like (this is the boxed warning material), and how the multi-year treatment course settles into a UAE family's life.

This page explains how the pathway works in 2026 for a UAE-resident patient: who qualifies, where the neurologist or psychiatrist conversation happens, where the prescription is written and filled, what the realistic out-of-pocket exposure band is in AED, what to monitor on therapy (depression and suicidality screening being the boxed-warning material for Huntington's patients), and how the longer-term treatment course fits into a UAE family's life. It is concierge documentation written for a family that is already in conversation with a treating neurologist or psychiatrist and wants the operational reality laid out plainly.

Why Austedo, and why now

Austedo is deutetrabenazine, a selective vesicular monoamine transporter type 2 (VMAT2) inhibitor. VMAT2 is the presynaptic transporter that packages dopamine and other monoamines into synaptic vesicles for regulated release. Inhibiting VMAT2 reduces presynaptic dopamine stores and dopaminergic neurotransmission. In hyperkinetic movement disorders, where excess dopaminergic signalling drives involuntary movements, this is therapeutically beneficial. The molecule was developed by Auspex Pharmaceuticals (acquired by Teva in 2015) as a deuterated analogue of the original VMAT2 inhibitor tetrabenazine (Xenazine). Deuteration at metabolically sensitive carbon positions slows CYP2D6-mediated clearance, smooths the PK curve, allows twice-daily (or once-daily Austedo XR) dosing rather than the thrice-daily schedule of tetrabenazine, and is associated with a lower incidence of depression-related adverse events than tetrabenazine in indirect comparisons.

The FDA approved Austedo in April 2017 for chorea associated with Huntington's disease in adults, expanded the label in August 2017 to include tardive dyskinesia in adults, and approved the once-daily Austedo XR extended-release formulation in February 2023. The pivotal Phase 3 programme (First-HD in Huntington's chorea; ARM-TD and AIM-TD in tardive dyskinesia) demonstrated meaningful improvement on the Unified Huntington Disease Rating Scale Total Maximal Chorea score and on the Abnormal Involuntary Movement Scale (AIMS) total score respectively, with tolerability profiles supporting chronic outpatient use.

For a UAE patient with confirmed Huntington's chorea where the chorea is impairing function or quality of life, or with moderate-to-severe tardive dyskinesia on a stable underlying psychiatric regimen where the dopamine-blocker cannot be discontinued or where the TD persists despite discontinuation, Austedo is the operational answer. The boxed warning for depression and suicidality in Huntington's patients is the central safety consideration and requires structured baseline and ongoing screening; this is the distinctive operational commitment for the Huntington's indication.

What Austedo is, in plain language

Austedo is an oral tablet. The immediate-release formulation is taken twice daily; the extended-release variant Austedo XR is taken once daily. Tablets are available in 6, 9, and 12 mg strengths (Austedo) and in 6, 12, 18, 24, 30, 36, 42, and 48 mg strengths (Austedo XR). Tablets are taken with food. Storage is room temperature; no refrigeration required. There is no infusion, no inpatient stay, no certified-centre requirement.

The titration schedule starts at 6 mg once daily for the first week, increases by 6 mg/day in weekly increments based on chorea or AIMS response and tolerability, and reaches a maintenance dose typically over 6 to 9 weeks. The maintenance range is 12 to 48 mg/day in divided doses (Austedo) or once daily (Austedo XR). The standard maintenance cap is 48 mg/day; a 36 mg/day cap applies for patients who are CYP2D6 poor metabolisers or who are on concurrent strong CYP2D6 inhibitors (fluoxetine, paroxetine, bupropion, quinidine).

For Huntington's chorea and tardive dyskinesia that respond, treatment is indefinite. The standard expectation is years of continuous use with periodic neurology or psychiatry review, structured depression and suicidality screening (boxed-warning material for Huntington's), tolerability assessment, and chorea or AIMS score documentation. The chronic-treatment shape is comparable to other long-term outpatient medication regimens.

Eligibility at a UAE neurology or psychiatry clinic

For UAE-resident patients, the neurology, movement disorders, and psychiatry services apply the FDA criteria:

For Huntington's chorea:

1. Confirmed diagnosis of Huntington's disease by HTT CAG repeat sizing through a clinical genetics laboratory (Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi, Tawam Hospital, American Hospital Dubai, and Mediclinic City Hospital). CAG repeat counts of 40 or more are fully penetrant; 36 to 39 are reduced-penetrance and require neurology and genetics consultation. 2. Clinically significant chorea documented on the Unified Huntington Disease Rating Scale Total Maximal Chorea score, typically a score of 8 or greater. 3. Baseline depression screening with the PHQ-9 or equivalent. Active suicidal ideation or untreated severe depression is a contraindication to starting Austedo; treatment of the underlying mood disorder must precede or accompany the Austedo conversation. 4. Baseline suicidality risk assessment with the C-SSRS or equivalent structured tool. 5. Baseline cognitive and functional assessment using the UHDRS battery and functional capacity scales.

For tardive dyskinesia:

1. Confirmed diagnosis of tardive dyskinesia by a neurologist or psychiatrist familiar with movement disorders, with documented chronic exposure to a dopamine-receptor blocking agent and characteristic involuntary movements scored on the AIMS or DISCUS. 2. Baseline AIMS or DISCUS score. 3. Stable underlying psychiatric or gastrointestinal condition. Discontinuing or switching the offending dopamine-blocker is the first-line consideration where clinically possible. 4. Baseline depression screening with the PHQ-9 or equivalent.

For both indications:

5. CYP2D6 genotype where available. Poor metabolisers require the 36 mg/day maintenance dose cap. 6. Drug interaction screen. Concurrent MAOI (or within 14 days of an MAOI) is a contraindication. Concurrent strong CYP2D6 inhibitors require the 36 mg/day cap. Concurrent reserpine, tetrabenazine, or valbenazine is contraindicated. 7. Baseline ECG where there is QT-prolongation concern (concurrent QT-prolonging medications or known cardiac conduction disease). 8. Pregnancy and lactation screen. Effective contraception is required during treatment. 9. Hepatic function review.

A UAE patient should arrive at the neurology or psychiatry conversation with the diagnostic workup: HTT CAG repeat report (for Huntington's), UHDRS chorea score documentation, or AIMS or DISCUS score documentation with dopamine-blocker exposure history (for tardive dyskinesia); baseline PHQ-9 and C-SSRS results; complete medication history; baseline ECG where indicated; and insurance pre-authorisation paperwork. Reserve Meds organises this documentation pack so the prescribing team can confirm eligibility on the first review.

The UAE prescribing and dispense picture, plainly

Austedo registration status at the Emirates Drug Establishment is variable. Where Austedo is registered and commercially supplied through Teva's regional distributor network, in-country dispensing applies. Where in-country registration is absent, a named-patient pathway can apply for documented physician-initiated prescriptions referencing FDA-approved indications, with cross-border procurement through Cigalah, Bin Sina, Gulf Pharmaceutical Industries, or comparable distributors. The functional supply chain is:

1. Prescribing physician: a board-certified UAE neurologist (movement disorders specialist preferred for Huntington's chorea) or a board-certified psychiatrist with movement-disorder experience (typical for tardive dyskinesia). Major UAE prescribing centres include Cleveland Clinic Abu Dhabi (with the movement disorders programme), American Hospital Dubai neurology and psychiatry, Mediclinic City Hospital neurology, Sheikh Shakhbout Medical City neurology, Burjeel Medical City neurology, NMC Specialty neurology, the Dr Sulaiman Al Habib network neurology, German Neuroscience Centre Dubai, Maudsley Health (NMC) Abu Dhabi for the TD subset, and Priory Wellbeing Centre Dubai. Public sector services at SKMC, Rashid, and Latifa Hospitals serve Emirati nationals on the equivalent pathway. 2. Diagnostic workup: HTT CAG repeat sizing for Huntington's cases runs through Cleveland Clinic Abu Dhabi clinical genetics, cross-border referral to KFSHRC Riyadh, or international genetic-testing laboratories. UHDRS chorea scoring is conducted at the prescribing centre. For tardive dyskinesia, AIMS or DISCUS scoring is conducted at the prescribing psychiatrist or neurologist's clinic with documented chronic dopamine-blocker exposure history. 3. Insurance pre-authorisation: most UAE private insurers (Daman, Thiqa for Emirati nationals; Oman Insurance, AXA Gulf, MetLife, Cigna, NEXtCARE, Bupa Global for commercial covers) cover VMAT2 inhibitor therapy for confirmed Huntington's chorea or moderate-to-severe TD. The high specialty-tier price point means commercial insurers typically require a clinical rationale letter documenting diagnosis confirmation (HTT CAG repeat report or AIMS or DISCUS score), baseline depression screening, and trial-of-alternatives where applicable. Pre-authorisation typically takes 7 to 21 days for a complete file. 4. Pharmacy dispense: 30-day supply at the prescribing centre's outpatient pharmacy or a partnered specialty pharmacy with the VMAT2 inhibitor inventory line. Teva's MENA commercial distributor network handles Austedo-branded supply where in-country registration applies. Named-patient cross-border procurement applies where in-country registration is absent. 5. Refill cycle: monthly. Continued dispensing typically requires documentation of ongoing chorea or AIMS score response, depression and suicidality screening, and tolerability assessment.

The 2026 pathway, step by step

Week 0 to 3: Reserve Meds builds the documentation pack with the treating neurologist's or psychiatrist's office. For Huntington's cases we coordinate HTT CAG repeat sizing (where not already documented), collect the UHDRS chorea score, the PHQ-9 and C-SSRS baseline results, the complete medication history, baseline ECG where indicated, and the insurance card details. For tardive dyskinesia cases we collect the AIMS or DISCUS score, the dopamine-blocker exposure history, the prescribing psychiatrist's coordinated decision on continuation or switching of the offending agent, the PHQ-9 baseline, and the insurance documentation. The prescribing office submits insurance pre-authorisation.

Week 3 to 5: Insurance pre-authorisation review. UAE commercial insurers typically turn this around within 1 to 3 weeks for a complete file with diagnosis confirmation.

Week 5 to 6: First dispense. Starting dose 6 mg once daily for the first week.

Week 6 to 14: Titration phase. Dose increased by 6 mg/day weekly based on chorea or AIMS response and tolerability, reaching the individualised maintenance dose typically over 6 to 9 weeks. Weekly clinical contact for depression and suicidality screening (PHQ-9), tolerability assessment, and extrapyramidal symptom monitoring.

Month 3 onwards: Maintenance dosing established. Monthly pharmacy refill. Monthly PHQ-9 and C-SSRS screening (more frequent for Huntington's patients per the boxed-warning monitoring schedule). Periodic AIMS or chorea score documentation at routine maintenance visits. ECG at the maintenance dose where indicated.

Ongoing: Maintenance dosing, monthly refill, monthly depression and suicidality screening for Huntington's patients (less intensive for stable tardive dyskinesia patients but baseline-anchored at each visit), periodic extrapyramidal symptom assessment, periodic chorea or AIMS scoring, periodic ECG where indicated.

Cost expectation in AED

US Austedo list price (2026) is approximately USD 8,000 to USD 10,000 per 30-day supply at the typical maintenance dose tier, with annual cost approximately USD 100,000 to USD 120,000 per patient at list price.

At indicative 2026 cross rates, a 30-day Austedo supply at USD 9,000 is approximately AED 33,000, and the annual cost at USD 110,000 is approximately AED 404,000.

For Emirati nationals with Thiqa coverage, VMAT2 inhibitor therapy for confirmed Huntington's chorea or moderate-to-severe TD is typically covered with documented diagnosis and prescriber rationale. Daman and other commercial covers vary; the prescribing physician's insurance liaison runs the pre-authorisation conversation. Out-of-pocket exposure for a covered patient is generally a co-payment band, not the full list price. For cash-pay or limited-cover cases, named-patient cross-border procurement may offer modest savings versus in-country specialty-tier pricing; this is case-specific.

Monitoring on therapy

The monitoring schedule for Austedo is structured around the boxed warning and the class effects:

- Depression and suicidality (boxed warning for Huntington's): PHQ-9 or equivalent at baseline, weekly during titration, monthly during maintenance, and at any clinical change. Structured suicidality assessment (C-SSRS) at baseline and at any clinical change in mood. Patient and family counselled at first prescription to report any new or worsening depression, suicidal thoughts, or behavioural change to the prescribing physician immediately. For Huntington's patients with advancing cognitive impairment, caregiver involvement is essential. For tardive dyskinesia patients the labelled population did not show the same suicidality signal, but baseline depression screening remains standard. - Extrapyramidal symptoms: clinical assessment for emergent parkinsonism, akathisia, dystonia, or neuroleptic malignant syndrome-like features at each visit. Dose reduction or discontinuation if parkinsonism or NMS-like features emerge. - Somnolence: clinical assessment for daytime sedation, particularly during titration. Driving and other safety-sensitive activities are restricted during titration and individually assessed at maintenance. UAE driving licence regulations are followed where neurological impairment is documented. - ECG: at baseline (if indicated) and at maintenance dose, particularly at the 48 mg/day ceiling. - Chorea or AIMS score: at baseline and at 4 to 6 week intervals during titration, then at routine maintenance visits. - CYP2D6 status: if not previously known, CYP2D6 genotyping at any titration plateau where adverse events suggest higher than expected drug exposure.

Religious, ethical, and family-logistics framing

Austedo is an oral small molecule. There is no animal-source material in standard manufacturing, no donor cells, no biological product. Halal and kosher acceptability are not in question. The classical Islamic jurisprudential framework for chronic medication in serious illness endorses VMAT2 inhibitor therapy for the labelled indications.

For Huntington's disease, the autosomal-dominant genetic implications for the wider family are a major feature of every case. Each child of an affected parent has a 50 percent risk of inheriting the expanded CAG allele. Structured genetic counselling for siblings, children, and extended family is part of standard care and routes through Cleveland Clinic Abu Dhabi clinical genetics, cross-border referral to KFSHRC Riyadh, or international genetic counselling services. In many UAE family structures the implications extend to marriage planning and to the family's own decision about predictive testing. The clinical genetics conversation is as important as the chorea-treatment conversation and runs in parallel.

For tardive dyskinesia, the patient carries a primary psychiatric or gastrointestinal diagnosis underneath the movement disorder. UAE psychiatric services handle the cases with discretion as standard practice; the medical record is confidential. The clinical conversation often involves family-confidentiality dimensions that are not always present for other chronic illnesses. Reserve Meds handles these cases with the same discretion.

For women of reproductive potential, effective contraception is required during treatment. The conversation needs to happen before prescribing, not at the first refill, and is documented by the prescribing physician.

The Austedo XR once-daily option simplifies the adherence schedule for patients who find the twice-daily schedule burdensome. Cost differential is modest and is generally a clinical-convenience decision.

When Austedo is not the right call

Austedo is the right answer for confirmed Huntington's chorea in adults and for moderate-to-severe tardive dyskinesia in adults. It is not the right answer for:

- Active suicidal ideation or untreated severe depression. Treatment of the underlying mood disorder must precede or accompany the Austedo conversation. - Concurrent MAOI use or use within 14 days of an MAOI (contraindicated). - Concurrent reserpine, tetrabenazine, or valbenazine (duplicate monoamine depletion, contraindicated). - Pregnant women without specialist counsel. Limited human data; an obstetric and neurology or psychiatry consultation is the appropriate first step. - Severe hepatic impairment without dose adjustment and structured monitoring. - Parkinsonian or akinetic-rigid syndromes (Austedo can worsen these).

For Huntington's chorea where Austedo is not the chosen agent, the alternatives in 2026 are tetrabenazine (original VMAT2 inhibitor, thrice-daily, higher depression signal), amantadine (NMDA receptor antagonist with weak antichoreic effect), pridopidine (in late-phase development, clinical-trial access only), atypical antipsychotics off-label (carries TD risk; reserved for chorea with behavioural or psychotic features), and multidisciplinary supportive care.

For tardive dyskinesia where Austedo is not the chosen agent, the alternatives are valbenazine (Ingrezza, the other VMAT2 inhibitor for TD; once-daily; similar efficacy in indirect comparisons), discontinuation or switching of the offending dopamine-blocker where clinically possible (first-line consideration), clozapine substitution where the patient requires ongoing antipsychotic therapy, botulinum toxin injection for focal dyskinetic movements, and supportive care.

Reserve Meds does not push a default. The page above describes the Austedo pathway because Austedo is the VMAT2 inhibitor the patient has asked about. If the conversation with the treating neurologist or psychiatrist points toward valbenazine, tetrabenazine, dose-blocker discontinuation, or another option, the operational pathway shifts accordingly. Where the patient's class has multiple Reserve Meds catalog entries (valbenazine and deutetrabenazine both being VMAT2 inhibitors for TD), we do not promote one VMAT2 inhibitor over another; the clinical decision is the prescribing physician's.

What Reserve Meds does on this case

We are a US-based concierge coordinator. We are not the prescriber and not the dispensing pharmacy. On a UAE Austedo case we build the documentation pack (HTT CAG repeat report for Huntington's, or AIMS or DISCUS score with dopamine-blocker exposure history for tardive dyskinesia; PHQ-9 and C-SSRS baseline; complete medication history; baseline ECG where indicated), submit first-review requests to the chosen prescribing centre, coordinate the insurance pre-authorisation conversation alongside the clinical workup, set up the first 30-day dispense at the chosen pharmacy, organise the structured depression and suicidality monitoring schedule (the boxed-warning material), and stay with the case through the first year of dosing with handoff to the local neurologist or psychiatrist for ongoing surveillance. Clinical decisions remain with your treating neurologist or psychiatrist.

---

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge coordinator; we are not the prescriber and not the dispensing pharmacy. Clinical decisions remain with your treating neurologist or psychiatrist.

Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-05-20.